Research programme: calcium-sensing receptor antagonists - NPS Pharmaceuticals/GlaxoSmithKline

Drug Profile

Research programme: calcium-sensing receptor antagonists - NPS Pharmaceuticals/GlaxoSmithKline

Alternative Names: Calcilytics - NPS Pharmaceuticals/GlaxoSmithKline; NPS 2143; NPS 89636; SB-262470; SKF 45675

Latest Information Update: 10 Aug 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NPS Pharmaceuticals
  • Class Naphthalenes; Pyrimidinones; Small molecules
  • Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 03 Aug 2011 Discontinued - Preclinical for Postmenopausal osteoporosis in USA (IV)
  • 03 Aug 2011 Discontinued - Preclinical for Postmenopausal osteoporosis in USA (PO)
  • 03 Aug 2011 Research programme: calcium-sensing receptor antagonists is no longer licensed to GlaxoSmithKline worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top